Engineered Protein Inhibitors of SARS-CoV-2 Entry: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 19: | Line 19: | ||
==Protein Inhibitor Development== | ==Protein Inhibitor Development== | ||
Protein inhibitors were thought of as a new idea for creating vaccines due to their smaller size and better stability compared to antibody vaccines<ref name="Cao">DOI:10.1126/science.abd9909</ref>. These protein inhibitors, also referred to as mini-binders, interact with the receptor binding domain of the spike protein, <scene name='10/1078124/Spikeblockedbyminibinder/ | Protein inhibitors were thought of as a new idea for creating vaccines due to their smaller size and better stability compared to antibody vaccines<ref name="Cao">DOI:10.1126/science.abd9909</ref>. These protein inhibitors, also referred to as mini-binders, interact with the receptor binding domain of the spike protein, <scene name='10/1078124/Spikeblockedbyminibinder/4'>preventing association of the viral cell with ACE2.</scene> | ||
[[Image:AHB2_Method.png|300 px|right|thumb|Figure 2: The use of the Rosetta Blueprint protein design to create the AHB2 inhibitor (7JZL & 7UHB).]] | [[Image:AHB2_Method.png|300 px|right|thumb|Figure 2: The use of the Rosetta Blueprint protein design to create the AHB2 inhibitor (7JZL & 7UHB).]] | ||
[[Image:LCB_Method.png|300 px|right|thumb|Figure 3:The use of the De Novo protein design to create the LCB1 and LCB3 inhibitors (7JZL).]] | [[Image:LCB_Method.png|300 px|right|thumb|Figure 3:The use of the De Novo protein design to create the LCB1 and LCB3 inhibitors (7JZL).]] | ||
